Funding agencies: The work reported in this article was supported by grants from the Van Alkemade-Keuls Foundation and the Prinses Beatrix Fonds (PBF; project no. WAR05–0120).
Risk factors for hallucinations in Parkinson's disease: Results from a large prospective cohort study
Article first published online: 20 MAR 2013
Copyright © 2013 Movement Disorder Society
Volume 28, Issue 6, pages 755–762, June 2013
How to Cite
Zhu, K., van Hilten, J. J., Putter, H. and Marinus, J. (2013), Risk factors for hallucinations in Parkinson's disease: Results from a large prospective cohort study. Mov. Disord., 28: 755–762. doi: 10.1002/mds.25389
Relevant conflicts of interest/financial disclosures: Nothing to report.
Full financial disclosures and author roles may be found in the online version of this article.
- Issue published online: 25 JUN 2013
- Article first published online: 20 MAR 2013
- Manuscript Accepted: 15 JAN 2013
- Manuscript Revised: 4 JAN 2013
- Manuscript Received: 15 JUN 2012
This article has been cited by:
- 1Can dopamine agonists trigger tactile hallucinations in patients with Parkinson's disease?, Journal of the Neurological Sciences, 2014,, , , ,
- 2Novel pharmaceuticals in the treatment of psychosis in Parkinson’s disease, Expert Review of Clinical Pharmacology, 2014, 7, 6, 779, , ,
- 4Predictors of dementia in Parkinson's disease; findings from a 5-year prospective study using the SCOPA-COG, Parkinsonism & Related Disorders, 2014, 20, 9, 980, , ,
- 5Sex differences in Parkinson’s disease, Journal of Clinical Neuroscience, 2014, 21, 9, 1503, , , , ,
- 6Should the maximum daily doses of levodopa be limited to 400mg/die?, Basal Ganglia, 2014, 4, 1, 29, , , , , , ,